Korro Bio reports FY 2023 net loss of $81.2M; cash of $166.1M funds operations into 2026

Korro Bio, Inc.

Net loss of $81.2M in 2023 vs. $58.0M in 2022; R&D expenses $57.2M (up from $42.2M).
Cash and short-term investments $166.1M as of Dec 31, 2023, compared to $55.2M at end of 2022.
Regulatory filing for KRRO-110 in Alpha-1 Antitrypsin Deficiency on track for H2 2024.
Preclinical data showed >50% editing using GalNAc conjugates with subcutaneous administration in mice.
Cash runway into 2026; interim clinical readout for KRRO-110 expected in H2 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Korro Bio, Inc. reported the year ended December 31, 2023 results: net income $81.2 million.

Period: the year ended December 31, 2023
Net income: $81.2 million
Result: reported results

Exact text from the filing

Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-077613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.